Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-05-31
2011-05-31
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C562S405000
Reexamination Certificate
active
07951843
ABSTRACT:
The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, R1R2, R3, R4, R5, R6, R7, and R8are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.
REFERENCES:
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 2002/0128319 (2002-09-01), Koo et al.
patent: WO 01/78721 (2001-10-01), None
patent: WO 03/008635 (2003-01-01), None
patent: WO 2006/045554 (2006-05-01), None
Vippagunta et. al., Advanced Drug Delivery Reviews, 2001, Elsevier, vol. 48, pp. 3-26.
Tagat et. al., Bioorganic and Medicinal Chemistry Letters, 1995, Pergamon, vol. 5, No. 18, pp. 2143-2146.
Lin et. al., Bioorganic and Medicinal Chemistry Letters, 1999, Pergamon, vol. 9, pp. 2747-2752.
Buchwald, H., et al. “Long-Term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis”, Surgery 88, p. 507 (1980).
During, M., et al. “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization”, Ann. Neurol. 25, p. 351 (1989).
Eriksen, J., et al. “NSAIDs and Enanatiomers of Flurbiprofen Target Gamma-Secretase and Lower A-beta-42 in vivo”, Journal of Clinical Investigation, New York, NY US vol. 112, No. 3, (2003), XP002311406.
Frautschy, S., et al. “Microglial Response to Amyloid Plaques in APPsw Transgenic Mice”, Am. J. of Pathology, VI. 52, No. 1 p. 307 (1998).
Goodson, J., “Medical Applications of Controlled Release”, vol. I, Chapter 6, pp. 115 (Table of Contents) (1984).
Howard, M., et al. “Acute Subdural Hematomas: An Age-Dependent Clinical Entity”, J. Neurosurgery, vol. 71, p. 858 (1989).
Huffman (Thompson), et al. “The Conversion of Phenols to the Corresponding Aryl Halides Under Mild Conditions”, Synthesis No. 4, p. 0547 (2005).
Hsiao, K., et al. “Correlative Memory Deficits, Aβ Elevation and Amyloid Plaques in Transgenic Mice”, Science 274, p. 99 (1996).
Ida, N., et al. “Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay”, J. Biol. Chem. 271, p. 22908 (1996).
Irizarry, M., et al. “APPswTransgenic Mice Develop Age-Related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1”, J. of Neuropathology and Experimental Neurology, vol. 56(9), p. 965 (1997).
Jensen, M., et al. “Quantification of Alzheimer Amyloid Peptides Ending at Residues 40 and 42 by Novel ELISA Systems”, Mol. Med. 6 p. 291 (2000).
Kawarabayahsi, T., et al. “Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease”, J. Neurosci. 21 p. 372 (2001).
Langer, R., “New Methods of Drug Delivery”, Science 249, p. 1527 (1990).
Langer and Peppas “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review”, Macromol. Chem. Phys. C23(1), 61-126 (1983).
Larner, A., “Secretases as Therapeutic Targets in Alzheimer's Disease: Patents 2000-2004”, Exp. Opinion Ther. Patents 14, p. 1403 (2004).
Lehman, J., et al. “Alterations in β-Amyloid Production and Deposition in Brain Regions of Two Transgenic Models”, Neurobiol. Aging 24, p. 645 (2003).
Levy, R., et al. “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled Release Diphosphonate”, Science 228, p. 190 (1985).
Lim, G., et al. Ibuprofen Effects on Alzheimer Pathology and Open Field Activity in APPsw Transgenic Mice, Neuroibol. Aging 22, p. 645 (2001).
Lim, G., et al. “Ibuprofen Suppresses Plaque Pathology and Open Field Activity in APPsw Transgenic Mice”, Journal of Neuroscience, vol. 20(15), p. 5709 (2000).
Marjaux, E., et al. “γ-Secretase Inhibitors: Still in the Running as Alzheimer's Therapeutics”, Drug Discovery Today: Therapeutics Strategies 1, p. 1 (2004).
Morihara, T., et al. “Selective Inhibition of Aβ42 Production b NSAID R-Enantiomer”, J., Neurochem. 83, p. 1009 (2002).
Myers, A., et al. “Use of Pseudo Ephedrine as a Practical Chiral Auxiliary for Asymmetric Synthesis”, Journal of American Chemical Society, 116 (20), p. 9361 (1994).
Nesmejanov, E., et al. “Immediate Cyanization of Ferricinium Salts”, Department for Organic Chemistry of the Moscow State University (Jul. 1960).
Peretto, D., et al. “Synthesis and Biological Activity of Fluriprofen Analogues as Selective Inhibitors of β-Amylid 1-42 Secretion”, J. Med. Chem. 48 p. 5705 (2005).
Saudek, C., et al. “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”, N. Engl. J. Med. p. 321 (1989).
Schweisguth, F., et al. Regulation of Notch Signaling Activity, Curr. Biol. 14, p. R129 (2004).
Sefton, M., “Implantable Pumps”, CRC Crit. Ref. Biomed. Eng. 14, p. 201 (1987).
Shimizu, K., et al. “Binding of Delta1, Jagged1, and Jagged2 to Notch2 Rapidly Induces Cleavage, Nuclear Translocation, and Hyperphosphorylation of Notch2”, Mol. Cell. Biol. 20, p. 6913 (2000).
Steiner, H., “Uncovering γ-Sucretase”, Curr. Alzheimer Research 1(3), p. 175 (2004).
Tanzi, R., et al. “Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective”, Cell, vol. 120, (2005), p. 545-555.
Thompson(Huffman), et al. “The Conversion of Phenols to the Corresponding Aryl Halides Under Mild Conditions”, Synthesis No. 4, p. 0547 (2005).
Vassar, R., et al. “β-Secretese Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE”, science 286, p. 735 (1999).
Wang, R., et al. “The Profile of Soluble Amyloid β Protein in Cultured Cell Media”, J. Biol. Chem. 271 p. 31894 (1996).
Weggen, S., et al. “A Subset of NSAIDs Lower Amylidogenic Aβ42 Independently of Cyclooxygenase Activity”, Nature 414, p. 212 (2001).
Yan, R., et al. “Membrane Anchored Aspartyl Protease with Alzheimer's Disease β Secretase Activity”, Nature 402, p. 533 (1999).
Yan, Q., et al. “Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease”, Journal of Neuroscience 23(20), p. 7504 (2003).
Xia, W., et al. “Preseilin 1 Regulates the Processing of β-Amyloid Precursor Protein C-Terminal Fragments and the Generation of Amyloid β-Protein in Endoplasmic Reticulum and Golgi”, Biochemistry 3, 16465 (1998).
Janssen Pharmaceutica N.V.
Padmanabhan Sreeni
Pihonak Sarah
Woodcock & Washburn LLP
LandOfFree
Amide linked modulators of γ-secretase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide linked modulators of γ-secretase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide linked modulators of γ-secretase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674076